Sensyne Health PLC's (LON:SENS) Chief Executive Lord Paul Drayson talks to Proactive London's Katie Pilbeam about their business model and how AI can transform our healthcare approach.
Their lead product GDm-Health which is managing diabetes in pregnancy was made available free to the NHS for the period of the pandemic to enable the NHS to adopt it more broadly, and is now used in more than half of NHS trusts within NHS England.
As a result over 13,000 babies have been born with the help of their software which 'reflects the potential' Drayson goes on to explain the 'revenue drivers' over the past year the company has signed its first major pharmaceutical collaboration – a £5mln deal with Bayer.
Sensyne also working with Roche to apply AI to trial design and has an agreement with Alexion.